News

As COVID-19 spread around the U.S., health care providers needed guidelines to treat patients—and they needed them fast.

The solution? A website that would house data- and expert-backed clinical treatment guidelines devised by a panel of U.S. physicians, statisticians, and other experts from the National Institutes of Health (NIH), universities, and health care organizations.

The Frederick National Laboratory led a collaborative project to build one, finishing in just two weeks.

The Pamoja Tulinde Maisha (PALM, Kiswahili for “together save lives”) trial, a large Ebola research effort supported by the Frederick National Laboratory, has received the David Sackett Trial of the Year Award for 2019.

In its urgent efforts to confront the novel coronavirus, the U.S. Food and Drug Administration (FDA) has tapped the Frederick National Laboratory for Cancer Research (FNL) to scientifically inform its decision-making on potential approval of blood tests for the presence of antibodies to SARS-CoV-2.

Three employees from Frederick National Laboratory’s Imaging and Visualization Group recently claimed a top spot of a computing and artificial intelligence challenge that attracted 170 competing groups from around the world.

A scientific paper on a member of the RAS family of oncogenes published last summer so intrigued Frederick National Laboratory computational scientist Trent Balius that he and his and colleagues performed a follow-up study, shedding more light on the topic.

Cancer is beginning to eclipse infectious disease as a major cause of mortality in low-to-middle income countries like those in sub-Saharan Africa. In Ethiopia, people with cancer who reach a hospital are diagnosed with advanced disease for which there is little treatment available and practically nothing to stem their unbearable disease-related pain. The Ethiopian government has made cancer treatment a health priority and is investing in new treatment centers and clinical services not previously available, such as radiation oncology.

Immune Response Induced by Vaccination May Lower Risk of New HPV Infections and Associated HPV-Related Cancers in Post-Transplant Women

A team from the Frederick National Laboratory’s Biopharmaceutical Development Program is developing a new autologous cell therapy line that uses engineered chimeric antigen receptor (CAR) T cells to treat acute myeloid leukemia, a particularly aggressive form of pediatric blood cancer. This foray into cell immunotherapy represents a new avenue of research and development for the BDP, which has traditionally focused on biologics to fight cancer, HIV, and rare diseases. 

Jason Evans is giving me a tour of the new NCI Program for Natural Products Discovery (NPNPD) facility when he pauses to look at a sample-handling robot under repair, its mechanical insides temporarily disemboweled. I ask if he has an electrical engineering background, and he laughs. Evans is a scientific programmer, but for him and his colleagues, that’s beside the point.

Discoveries by AIDS researcher Brandon F. Keele, Ph.D. have not only put him on the leading edge of research to prevent and treat HIV infection. He’s also influenced the work of his peers.

Keele, a principal investigator and senior principal scientist in the AIDS and Cancer Virus Program at the Frederick National Laboratory was named a Highly Cited Researcher by Web of Science, a global citation database. Keele and colleague Jeffrey Lifson, M.D. were recognized for producing papers that ranked in the top 1 percent by citations for their field.